Ether Oxygen Single Bonded To Carboxylic Acid, Percarboxylic Acid Or Salt Thereof Through An Acyclic Carbon Or Acyclic Carbon Chain Patents (Class 514/571)
  • Patent number: 9849180
    Abstract: What is described is a semi-solid controlled release composition comprising a semi-solid lipid pharmaceutical active agent in a solution or a homogenous suspension, methods of using the composition for treating a disease, and methods of manufacturing the composition.
    Type: Grant
    Filed: September 14, 2015
    Date of Patent: December 26, 2017
    Inventors: Hui Rong Shen, Na Gan
  • Patent number: 9822057
    Abstract: There is provided individual polymorphic forms of treprostinil and pharmaceutical formulations comprising the same, methods of making and using the same.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: November 21, 2017
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, Michael Scannell
  • Patent number: 9782373
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: January 24, 2017
    Date of Patent: October 10, 2017
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Patent number: 9498458
    Abstract: A compound of Formula (I) or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein Formula (I), m, n, X1 and X2 are as defined herein, is useful for inhibiting, reducing, or treating fibrosis, conditions leading to or arising from it, and/or negative effects of each thereof.
    Type: Grant
    Filed: June 1, 2015
    Date of Patent: November 22, 2016
    Assignee: MediciNova, Inc.
    Inventors: Kazuko Matsuda, Yuichi Iwaki
  • Patent number: 9422223
    Abstract: This invention pertains generally to prostacyclin formulations and methods for their use in promoting vasodilation, inhibiting platelet aggregation and thrombus formation, stimulating thrombolysis, inhibiting cell proliferation (including vascular remodeling), providing cytoprotection, preventing atherogenesis and inducing angiogenesis.
    Type: Grant
    Filed: October 13, 2015
    Date of Patent: August 23, 2016
    Assignee: United Therapeutics Corporation
    Inventors: Ken Phares, David Mottola, Roger Jeffs
  • Patent number: 9358217
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) in human subjects.
    Type: Grant
    Filed: November 13, 2014
    Date of Patent: June 7, 2016
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Patent number: 9308206
    Abstract: Certain embodiments are directed to methods of treating a pathophysiological state or symptoms thereof resulting from aldose reductase-mediated signaling in a cytotoxic pathway using an aldose reductase specific inhibitor.
    Type: Grant
    Filed: January 27, 2014
    Date of Patent: April 12, 2016
    Assignee: THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Satish K Srivastava, Kota V Ramana
  • Patent number: 9255064
    Abstract: Prostacyclin compounds and compositions comprising the same are provided herein. Specifically, prostacyclin compounds comprising treprostinil covalently linked to a linear C5-C18 alkyl, branched C5-C18 alkyl, linear C2-C18 alkenyl, branched C3-C18 alkenyl, aryl, aryl-C1-C18 alkyl or an amino acid or a peptide (e.g., dipeptide, tripeptide, tetrapeptide) are described. The linkage, in one embodiment, is via a carbamate, amide or ester bond. Prostacyclin compounds provided herein can also include at least one hydrogen atom substituted with at least one deuterium atom. Methods for treating pulmonary hypertension (e.g., pulmonary arterial hypertension) and portopulmonary hypertension are also provided.
    Type: Grant
    Filed: March 6, 2015
    Date of Patent: February 9, 2016
    Assignee: Insmed Incorporated
    Inventors: Vladimir Malinin, Walter Perkins, Franziska Leifer, Donna Konicek, Zhili Li, Adam Plaunt
  • Patent number: 9115073
    Abstract: The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
    Type: Grant
    Filed: December 28, 2012
    Date of Patent: August 25, 2015
    Assignee: GENFIT
    Inventors: Mathieu Dubernet, Jean-Francois Delhomel, Karine Bertrand
  • Publication number: 20150139987
    Abstract: Treatment of homozygous familial hypercholesterolemia by administration of (R)-2-(4-((2-ethoxy-3-(4-(trifluoromethyl)phenoxy)propyl)thio)-2-methylphenoxy)acetic acid or a salt thereof, optionally in combination with an MTP inhibitor, an apoB-100 synthesis inhibitor, or a PCSK9 inhibitor.
    Type: Application
    Filed: November 14, 2014
    Publication date: May 21, 2015
    Applicant: CymaBay Therapeutics, Inc.
    Inventors: Robert L. Martin, Charles A. McWherter, Patrick J. O'Mara
  • Publication number: 20150119458
    Abstract: The present invention discloses a 4-((substituted phenyl)difluoromethyl)phenoxycarboxylic acid derivative and preparation process and use thereof. More specifically, the present invention relates to a compound of the following formula I, which is defined in the specification. The compounds according to the present invention can be used as PPAR agonists, and demonstrates a strong effect on reducing the levels of total cholesterol (TC), triglyceride (TG), and low density lipoprotein cholesterol (LDL-C) in blood plasma, and thus the compound according to the present invention can be used in the preparation of a medicament for treating or preventing hyperlipoidemia or cardio-cerebrovascular diseases caused by hyperlipoidemia, such as diabetes, atherosclerosis, stroke, coronary heart disease, etc. The present invention also relates to a novel intermediate compound for the preparation of the compound of formula I and preparation method thereof.
    Type: Application
    Filed: April 25, 2013
    Publication date: April 30, 2015
    Applicant: Zhejiang Hisun Pharmaceutical Co., Ltd.
    Inventors: Hua Bai, Jian Hong, Lifeng Cai, Hegeng Wei, Xiaoyu Liu, Xiaohe Zheng
  • Patent number: 9012509
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic steatohepatitis (NASH) and/or reducing one or more of hepatic fibrosis, lobular inflammation, and hepatocellular ballooning.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: April 21, 2015
    Assignee: MedicNova, Inc.
    Inventor: Kazuko Matsuda
  • Patent number: 8993629
    Abstract: The invention relates to a viscoelastic system for drift reduction for pesticidal formulations, and the use thereof, wherein said formulation comprising at least one nitrogen-based cationic surfactant and at least one pesticide, wherein said pesticide contains at least one acid functional group associating with said cationic surfactant thereby forming a viscoelastic formulation.
    Type: Grant
    Filed: September 1, 2009
    Date of Patent: March 31, 2015
    Assignee: Akzo Nobel N.V.
    Inventor: Jinxia Susan Sun
  • Publication number: 20150080471
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) in human subjects.
    Type: Application
    Filed: November 13, 2014
    Publication date: March 19, 2015
    Applicant: MEDICINOVA, INC.
    Inventor: Kazuko MATSUDA
  • Patent number: 8968775
    Abstract: Provided are pharmaceutical carriers based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.
    Type: Grant
    Filed: March 14, 2014
    Date of Patent: March 3, 2015
    Assignee: EyeCRO, LLC
    Inventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
  • Patent number: 8962687
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting liver steatosis, lobular inflammation, hepatic ballooning and hepatic scarring.
    Type: Grant
    Filed: January 10, 2014
    Date of Patent: February 24, 2015
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20150051145
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: October 24, 2014
    Publication date: February 19, 2015
    Applicant: Genfit
    Inventors: Raphael DARTEIL, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Publication number: 20150051235
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: October 21, 2014
    Publication date: February 19, 2015
    Applicant: Infirst Healthcare Limited
    Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
  • Publication number: 20150045610
    Abstract: Methods and compositions for modifying fertility and/or spermatogenesis or spermiogenesis in a male mammalian subject involve administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of one or more T1R3 receptors or an intermediate in the signaling pathways thereof in the subject's testis cells or germ cells. In another embodiment, the method further involves administering to the subject or contacting the subject's testis cells, germ cells or sperm with a composition that modifies the activation, nucleic acid expression, protein expression, signaling or activity of G-?-gustducin, or an intermediate in the signaling pathways thereof. Methods for screening a test molecule for its effect on spermatogenesis or spermiogenesis or fertility and compositions for modifying spermatogenesis or spermiogenesis or fertility in a mammalian subject, e.g.
    Type: Application
    Filed: April 10, 2013
    Publication date: February 12, 2015
    Inventor: Bedrich Mosinger
  • Publication number: 20150031769
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for reducing blood levels of one or more of triglycerides (TG), total cholesterol (TC) and low density lipoprotein (LDL) in human subjects.
    Type: Application
    Filed: July 23, 2014
    Publication date: January 29, 2015
    Applicant: MEDICINOVA, INC.
    Inventor: Kazuko MATSUDA
  • Publication number: 20150017099
    Abstract: The invention provides methods and compositions for the diagnosis, prognosis and treatment of respiratory tract diseases. Specifically, the invention provides diagnosis, prognosis and treatment of respiratory infections using bitter and sweet taste signal transduction pathways. In one aspect, the invention relates to a method for treating a respiratory infection by administering a composition to the respiratory tract of a subject in an amount capable of activating bitter taste signaling and/or inhibiting sweet taste signaling. The composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract. In another aspect, the invention relates to a composition for treatment of a respiratory infection. Such composition comprises at least a bitter receptor agonist and, optionally, a pharmaceutically acceptable carrier for delivering the composition to the respiratory tract.
    Type: Application
    Filed: January 25, 2013
    Publication date: January 15, 2015
    Inventors: Noam A. Cohen, Robert J. Lee, Danielle R. Reed
  • Publication number: 20150018422
    Abstract: Provided is an aromatic ring compound having a GPR40 agonist activity. A compound represented by the formula (I): wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity, and is useful as an agent for the prophylaxis or treatment of diabetes and the like.
    Type: Application
    Filed: February 12, 2013
    Publication date: January 15, 2015
    Inventors: Seiji Miwatashi, Hideo Suzuki, Tomohiro Okawa, Yasufumi Miyamoto, Takeshi Yamasaki, Yuko Hitomi, Yasuhiro Hirata, Akito Shibuya
  • Publication number: 20150005385
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
    Type: Application
    Filed: September 15, 2014
    Publication date: January 1, 2015
    Applicant: MediciNova, Inc.
    Inventor: Kazuko MATSUDA
  • Publication number: 20140350112
    Abstract: The present invention relates to novel 1,3-diphenylpropane derivatives, pharmaceutical compositions comprising the same and therapeutic uses thereof, in particular in the fields of human and animal health. The compounds according to the present invention have intrinsic PPAR agonist properties. They are therefore of particular interest in the treatment of metabolic and/or inflammatory diseases and particularly peripheral and central diseases associated with the metabolic syndrome, such as diverse forms of steatohepatitis, type 2 diabetes, diverse neurodegenerative disorders, such as Alzheimer's disease, Parkinson's disease and multiple sclerosis.
    Type: Application
    Filed: December 28, 2012
    Publication date: November 27, 2014
    Applicant: GENFIT
    Inventors: Mathieu Dubernet, Jean-Francois Delhomel, Karine Bertrand
  • Patent number: 8895536
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: November 25, 2014
    Assignee: Infirst Healthcare Ltd.
    Inventors: Robin Mark Bannister, John Brew, Wilson Caparros-Wanderley, Gregory Alan Stoloff, Suzanne Jane Dilly, Gemma Szucs, Olga Pleguezuelos Mateo
  • Patent number: 8895537
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a cardiovascular disease in an individual using such pharmaceutical compositions.
    Type: Grant
    Filed: February 3, 2012
    Date of Patent: November 25, 2014
    Assignee: Infirst Healthcare Ltd.
    Inventors: Robin Mark Bannister, John Brew, Suzanne Jane Dilly, Gregory Alan Stoloff, Wilson Caparros-Wanderley
  • Patent number: 8895619
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: May 28, 2014
    Date of Patent: November 25, 2014
    Assignee: Genfit
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Patent number: 8883233
    Abstract: Disclosed is an animal feed composition that comprises free indole acetic acid (free IAA) or a derivative thereof. Also disclosed is a method for enhancing animal growth by feeding the animal with a composition according to the invention. Further disclosed is the use of free IAA or a derivative thereof in a method of therapy of animals in need of a growth-promoting treatment, such as immunocompromised animals, animals with a growth deficit or slow-growing animals. Disclosed is the use of free IAA or a derivative thereof for the preparation of a therapeutical composition for increasing the growth rate and/or the feed conversion rate and/or the immunity of animals in need of such a treatment, in particular, immunocompromised or slow-growing animals. A composition may be in the form of a food or feed supplement.
    Type: Grant
    Filed: July 13, 2012
    Date of Patent: November 11, 2014
    Assignee: Veijlen N.V.
    Inventors: Hurbert Jean Marie Francois Gillessen, Christian Rebiere
  • Patent number: 8877685
    Abstract: An aqueous liquid herbicide composition comprising a solution of at least one of 2,4-D and dicamba in the form of the monomethylamine salt and at least one of 2,4-D and dicamba in the form of the dimethylamine salt wherein the molar ratio of monomethylamine to dimethylamine is in the range of from 1:20 to 4:6.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: November 4, 2014
    Assignee: Nufarm Australia Limited
    Inventors: Chad Richard Ord Sayer, Graeme Sutton, Aristos Panayi
  • Publication number: 20140309165
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as amino-transferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Application
    Filed: May 28, 2014
    Publication date: October 16, 2014
    Applicant: GENFIT
    Inventors: Raphael DARTEIL, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Publication number: 20140296341
    Abstract: The present invention relates to formulations comprising a solid dispersion product of an active agent having at least one of a hydrogen bond donor moiety (e.g. ibuprofen, fenofibric acid or naproxen) and a proton donor moiety and a pharmaceutically acceptable polyvinyllactam polyvinylacetate poly(alkylene glycol) graft copolymer, and to methods for preparing such formulations.
    Type: Application
    Filed: September 21, 2012
    Publication date: October 2, 2014
    Inventors: Samuel Kyeremateng, Gerd Woehrle, Svenja Warnecke, Simon Kullmann, Ullrich Westedt, Jürgen Weis
  • Publication number: 20140275263
    Abstract: Provided are pharmaceutical carriers suitable based on oil-in-water microemulsions and methods of making same. Also provided are pharmaceutical compositions comprising a carrier of the invention and a lipophilic active pharmaceutical ingredient (API), as well as methods for making same. The pharmaceutical compositions are particularly suitable for use in formulating lipophilic APIs for topical administration to the eye. Specifically included are pharmaceutical compositions comprising fenofibrate or fenofibric acid as API. Also provided is a method of treating a disease of the posterior segment of the eye. Also provided is a pharmaceutical composition comprising a compound represented by formulated for topical administration to the eye.
    Type: Application
    Filed: March 14, 2014
    Publication date: September 18, 2014
    Applicant: EyeCRO, LLC
    Inventors: Ronald A. Wassel, Fadee G. Mondalek, Rafal A. Farjo, Alexander B. Quiambao, Didier J. Nuño
  • Patent number: 8835499
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic fatty liver disease (NAFLD) or non-alcoholic steatohepatitis (NASH).
    Type: Grant
    Filed: December 5, 2012
    Date of Patent: September 16, 2014
    Assignee: MediciNova, Inc.
    Inventor: Kazuko Matsuda
  • Publication number: 20140255480
    Abstract: The invention relates to a pharmaceutical formulation of nanonised fenofibrate, to a method for preparing same, and to the uses thereof.
    Type: Application
    Filed: April 7, 2014
    Publication date: September 11, 2014
    Applicant: ETHYPHARM
    Inventors: Catherine HERRY, Pascal OURY
  • Publication number: 20140248341
    Abstract: Pharmaceutical formulations that resist ethanol-induced dose dumping and methods of use thereof.
    Type: Application
    Filed: April 29, 2014
    Publication date: September 4, 2014
    Applicant: ALKERMES PHARMA IRELAND LIMITED
    Inventors: Gary Liversidge, David Manser, Shah Hardik, Stephen B. Ruddy, Gurvinder S. Rekhi
  • Publication number: 20140243267
    Abstract: The present invention relates to methods and compositions for the prevention and treatment of keratin-based skin diseases. In particular, the application describes compositions and methods of treating a patient suffering from skin blistering comprising the use of phase II enzyme inducers.
    Type: Application
    Filed: September 12, 2013
    Publication date: August 28, 2014
    Applicant: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Pierre A. Coulombe, Michelle L. Kerns
  • Publication number: 20140243378
    Abstract: Disclosed are methods of treating a muscle disease and improving normal muscle function by administering a therapeutically effective amount of an isoprenoid antibiotic. Also disclosed are methods of upregulating hnRNP L and hnRNP L targets by administering a therapeutically effective amount of an isoprenoid antibiotic. Methods of screening compounds for use in treating muscle disease and improving muscle function are also described.
    Type: Application
    Filed: October 19, 2012
    Publication date: August 28, 2014
    Applicants: Tufts Medical Center, Inc., Children's Medical Center Corporation
    Inventors: Isabelle Draper, Louis M. Kunkel, Matthew S. Alexander, Alan S. Kopin
  • Publication number: 20140199376
    Abstract: Disclosed are methods of treating subjects having conditions related to angiogenesis including administering an effective amount of a polymeric Nanoparticle form of thyroid hormone agonist, partial agonist or an antagonist thereof, to promote or inhibit angiogenesis in the subject. Compositions of the polymeric forms of thyroid hormone, or thyroid hormone analogs, are also disclosed.
    Type: Application
    Filed: February 20, 2014
    Publication date: July 17, 2014
    Applicant: NanoPharmaceuticals LLC
    Inventors: Shaker A. Mousa, Faith B. Davis, Paul J. Davis
  • Patent number: 8772342
    Abstract: The invention provides 1,3-diphenylprop-2-en-1-one derivatives and pharmaceutical compositions comprising the same for treating liver disorders, in particular those requiring the reduction of plasma level of biochemical markers such as aminotransferases. The 1,3-diphenylprop-2-en-1-one derivatives of General Formula (I) have hepatoprotective properties and can be used in methods for treating liver disorders involving the pathological disruption, inflammation, degeneration, and/or proliferation of liver cells, such as liver fibrosis or fatty liver disease.
    Type: Grant
    Filed: November 26, 2010
    Date of Patent: July 8, 2014
    Assignee: GENFIT
    Inventors: Raphael Darteil, Rémy Hanf, Dean Hum, Ingrid Dufour
  • Publication number: 20140187561
    Abstract: In one aspect, the present invention relates to a formulation in the form of molecular dispersion comprising i) fenofibric acid, a physiologically acceptable salt or derivative thereof and optionally other active substances, ii) a binder component comprising at least one enteric binder, and optionally iii) other physiologically acceptable excipients. In a second aspect, the present invention relates to novel salts of fenofibric acid that are photostable when compared to other salts of fenofibric acid.
    Type: Application
    Filed: July 29, 2013
    Publication date: July 3, 2014
    Inventors: Russell Drew Cink, Joseph B. Paterson, Jr., Yi Gao, Geoff G.Z. Zhang, Michelle A. Long, John B. Morris, Joerg Rosenberg
  • Patent number: 8765813
    Abstract: The present disclosure relates to novel methods for using treprostinil or its derivative, or a pharmaceutically acceptable salt thereof, for the treatment and/or prevention of ischemic lesions, such as digital ulcers, in subjects with scleroderma (including systemic sclerosis), Buerger's disease, Raynaud's disease, Raynaud's phenomenon and/or other conditions that cause such lesions. The disclosure also relates to kits for treatment and/or prevention of ischemic lesions, which include an effective amount of treprostinil or its derivative, or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: December 16, 2004
    Date of Patent: July 1, 2014
    Assignee: United Therapeutics Corporation
    Inventors: Michael Wade, Roger Jeffs, Robert Roscigno, Deborah Strootman, Kathryn Bronstein
  • Publication number: 20140155484
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for inhibiting liver steatosis, lobular inflammation, hepatic ballooning and hepatic scarring.
    Type: Application
    Filed: January 10, 2014
    Publication date: June 5, 2014
    Applicant: MediciNova, Inc.
    Inventor: Kazuko MATSUDA
  • Publication number: 20140155485
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: June 5, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: Robin M. Bannister, John Brew, Wilson Caparros-Wanderely, Suzanne J. Dilly, Olga Pleguezeulos Mateo, Gregory A. Stoloff
  • Patent number: 8734769
    Abstract: This invention pertains to methods and compositions for the diagnosis and treatment of cardiovascular conditions. More specifically, the invention relates to isolated molecules that can be used to diagnose and/or treat cardiovascular conditions including cardiac hypertrophy, myocardial infarction, stroke, arteriosclerosis, and heart failure.
    Type: Grant
    Filed: March 8, 2013
    Date of Patent: May 27, 2014
    Assignee: The Brigham and Women's Hospital, Inc.
    Inventor: Richard T. Lee
  • Patent number: 8735632
    Abstract: The invention relates to novel polyglycerol based UV-filters as well as to topical compositions comprising such novel polyglycerol based UV-filters. Furthermore, the invention relates to the use of such novel polyglycerol based UV-filters to enhance the solubility of butyl methoxydibenzoylmethane or bis-ethylhexyloxyphenol methoxyphenyl triazine in cosmetic oils.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: May 27, 2014
    Assignee: DSM IP Assets B.V.
    Inventor: Alexander Schlifke-Poschalko
  • Patent number: 8722083
    Abstract: Various fenofibrate compositions include a plurality of first granules having a high bioavailability in vivo, and a plurality of second granules having a low bioavailability in vivo. The first granules may comprise fenofibrate, from 0.3% to 10% by weight of the first granules of a first surfactant, and a first water soluble or water dispersible cellulose derivative, and the second granules may comprise fenofibrate, from 0% to 0.25% by weight of the second granules of a second surfactant, and a second water soluble or water dispersible cellulose derivative.
    Type: Grant
    Filed: June 25, 2012
    Date of Patent: May 13, 2014
    Assignee: Mylan, Inc.
    Inventors: Sarat C. Chattaraj, Glenn Allen Redelman, Andrew Alan Shaw
  • Publication number: 20140128473
    Abstract: A compound of Formula (I): or a metabolite thereof, or an ester of the compound of Formula (I) or the metabolite thereof, or a pharmaceutically acceptable salt of each thereof, wherein m, n, X1 and X2 are as defined herein, is useful for treating non-alcoholic steatohepatitis (NASH) and/or reducing one or more of hepatic fibrosis, lobular inflammation, and hepatocellular ballooning.
    Type: Application
    Filed: January 10, 2014
    Publication date: May 8, 2014
    Applicant: MediciNova, Inc.
    Inventor: Kazuko MATSUDA
  • Publication number: 20140128354
    Abstract: The present specification discloses pharmaceutical compositions, methods of preparing such pharmaceutical compositions, and methods and uses of treating a chronic inflammation and/or an inflammatory disease in an individual using such pharmaceutical compositions.
    Type: Application
    Filed: January 14, 2014
    Publication date: May 8, 2014
    Applicant: BIOCOPEA LIMITED
    Inventors: Robin M. Bannister, John Brew
  • Publication number: 20140128439
    Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
    Type: Application
    Filed: August 7, 2013
    Publication date: May 8, 2014
    Applicant: Metabolex, Inc.
    Inventors: Brian Edward Lavan, Gopal Chandra Saha, Brian K. Roberts, Charles A. McWerther
  • Publication number: 20140128438
    Abstract: Methods of treating gout flares comprising administering a composition comprising a first urate-lowering agent are disclosed. In some aspects, the first urate-lowering agent is (?)-halofenate, (?)-halofenic acid, or a pharmaceutically acceptable salt thereof. Other aspects provide for methods of reducing the number, duration, frequency or intensity of gout flares experienced by a subject.
    Type: Application
    Filed: November 2, 2012
    Publication date: May 8, 2014
    Inventors: Brian Edward Lavan, Gopal Chandra Saha, Charles A. McWherter, Brian K. Roberts